





Supplemental Figure 1: Meningococcal serogroup B CPS polymers from an LOS-deficient (*lpxA*) mutant (CPS-*lpxA*) induced inflammatory cytokines, chemokines and nitric oxide release from murine macrophages. RAW264 cells (250×10^3 /well) in 96-well plates induced with CPS-*lpxA* polymers overnight. Cytokine release was quantified by ELISA and nitric oxide release was quantified as nitrite accumulation by the Greiss method. **A:** TNF α ; **B:** Nitric oxide; **C:** IP-10 (CXCL10) and **D:** MIP-2 release. Unstimulated macrophages incubated simultaneously were used as the control. Error bars represent SD from the mean of quadruplicate readouts. The results are representative of 3 independent experiments.

A**RAW 264.7 cells (TLR4-sufficient)**


B**ScCr cells (TLR4-deficient)**

Supplemental Figure 2: Meningococcal capsular polysaccharides induce nitric oxide release from TLR4-sufficient and TLR4-deficient murine macrophages. **A:** Dose-dependent release of nitric oxide from RAW264 (TLR4-sufficient) induced with meningococcal CPS from serogroups A, B, C, W135, Y, the vaccine grade serogroup A CPS (MAPS) and from the serogroup B CPS-*lpxA* deficient strain. **B:** ScCr (TLR4-deficient) cells induced with 50 μg of meningococcal CPS polymers. Pam3CSK4, a synthetic TLR2 ligand, was used as a control. Stimulated cells were incubated overnight and nitrite accumulation was measured by the Greiss method. Unstimulated cells were used as controls. The results are representative of 3 independent determinations.

A


B

C HEK/TLR2 stably transfected cells



Supplemental Figure 3: The lipid A antagonist E5564 exerts inhibitor effects only in TLR4-expressing cells. **A:** Mouse TNF α release from RAW264 macrophages stimulated with meningococcal CPS-*lpxA* doses in presence of E5564 (1 μ g/ml). **B:** Nitrite release quantified in the same supernatants of RAW264 induced as in panel A using the Griess method. **C:** E5564 does not inhibit TLR2 mediated recognition of meningococcal CPS-*lpxA* polymer. IL-8 release from stably transfected HEK/TLR2 cells induced with serogroup B CPS-*lpxA* with or without E5564 doses 0.5, 1 or 2.5 μ g/ml. **D:** Eritoran inhibits IL-6 release from THP-1 cells induced with meningococcal CPS polymers purified from serogroup A (CPS-A) or from wild type serogroup B (CPS-B) in presence of E5564 at 1 μ g/ml. TNF α , IL-8 and IL-6 release was measured by ELISA. Error bars represent SD from the mean of quadruplicate readouts. The results are representative of 2 independent experiments.


THP-1 cells




Supplemental Figure 4: MAP kinases mediated TNFa release induced by meningococcal CPS polymers. Signaling pathways was inhibited with specific MAP kinase chemical inhibitors that target p38, JNK and MEK/ERK signaling and used at 10mM in THP-1 cells for 30 min prior to stimulation with CPS polymers. TNFa release was quantified by ELISA and error bars represent \pm SD from the mean of 4 independent wells.

RT² PCR Array


Gene expression profiles in THP-1 cells induced with TLR ligand




TLR4 antagonist
Rhizobium LPS



TLR4 agonist
Meningococcal LPS



TLR4-MD-2/TLR2 agonist
Meningococcal capsule (CPS)



Supplemental Figure 5: Differential gene induction in THP-1 cells induced by CPS-*lpxA*. **A:** Real-Time PCR microarrays (RT² profiler™ PCR Array, SABiosciences) gene induction profiles of THP-1 cells induced with meningococcal NMB LOS (2 pmole/ml~4ng/ml) or with CPS-*lpxA* (10μg/ml) or with the TLR4 antagonist Rhizobium LPS (5 μg/ml) for 18 hr (see Methods section). **B, C** and **D:** Schematic 3-D presentation of genes induction magnitude and profiles induced by meningococcal LOS, CPS and Rhizobium LPS respectively.